QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)
QQQ   426.91 (+0.25%)
AAPL   167.63 (-0.22%)
MSFT   412.94 (+0.27%)
META   497.50 (+0.67%)
GOOGL   155.70 (+0.15%)
AMZN   181.90 (+0.34%)
TSLA   151.57 (-2.50%)
NVDA   848.00 (+0.91%)
AMD   154.40 (+0.25%)
NIO   3.90 (-0.26%)
BABA   69.10 (+0.41%)
T   16.12 (+0.19%)
F   12.06 (+0.17%)
MU   117.30 (+0.83%)
GE   155.77 (+0.06%)
CGC   6.50 (+0.15%)
DIS   112.90 (-0.04%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.47 (+0.33%)
XOM   118.80 (+0.14%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$0.37
-5.2%
$0.68
$0.20
$7.41
$2.52M1.42432,496 shs119,671 shs
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
$0.00
$0.00
$0.00
$60K1.2169,282 shs1,167 shs
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
$0.00
$0.00
$0.00
$0.01
$930K1.499.66 million shs1.90 million shs
Q BioMed Inc. stock logo
QBIO
Q BioMed
$0.00
$0.00
$0.02
$10K1.72538 shsN/A
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-4.61%-0.27%-34.32%-76.72%-94.75%
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
0.00%0.00%-50.00%-87.50%-88.89%
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
+12.50%+12.50%-57.14%-10.00%-86.26%
Q BioMed Inc. stock logo
QBIO
Q BioMed
0.00%-66.67%-50.00%-83.33%-99.32%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
2.4423 of 5 stars
3.32.00.04.00.60.00.0
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/AN/AN/AN/AN/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
2.50
Moderate Buy$8.502,211.35% Upside
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/AN/A

Current Analyst Ratings

Latest QBIO, GSTC, AMBS, and AGRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2024
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
$19.59M0.13N/AN/A($5.51) per share-0.07
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/AN/AN/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
$280K0.00N/AN/A($0.11) per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
-$14.47M-$9.84N/AN/A-73.83%N/A-179.07%5/9/2024 (Estimated)
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/A0.00N/AN/AN/AN/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
-$1.95MN/A0.00N/AN/AN/A-75,007.21%N/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
-$2.05M-$0.030.00N/AN/AN/AN/AN/A5/26/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/AN/AN/AN/AN/A
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/AN/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
N/AN/AN/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
N/A
0.46
0.33
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/AN/AN/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
N/AN/AN/A
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
10.92%
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
N/A
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
0.01%
Q BioMed Inc. stock logo
QBIO
Q BioMed
N/A

Insider Ownership

CompanyInsider Ownership
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
0.50%
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
10.33%
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
2.50%
Q BioMed Inc. stock logo
QBIO
Q BioMed
28.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Agile Therapeutics, Inc. stock logo
AGRX
Agile Therapeutics
226.86 million6.82 millionNot Optionable
Amarantus BioScience Holdings, Inc. stock logo
AMBS
Amarantus BioScience
12630.41 million565.29 millionNot Optionable
GlobeStar Therapeutics Co. stock logo
GSTC
GlobeStar Therapeutics
11.16 billion1.13 billionNot Optionable
Q BioMed Inc. stock logo
QBIO
Q BioMed
3145.10 million104.18 millionNot Optionable

QBIO, GSTC, AMBS, and AGRX Headlines

SourceHeadline
E&Q Master Cordless Gutta Percha Obturator from Meta BioMedE&Q Master Cordless Gutta Percha Obturator from Meta BioMed
news-medical.net - March 24 at 4:19 AM
Clearside Biomedical Q4 2023 Earnings PreviewClearside Biomedical Q4 2023 Earnings Preview
msn.com - March 11 at 7:34 PM
Q BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and Dates
benzinga.com - February 24 at 3:23 AM
Biogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue Estimates
msn.com - February 13 at 1:26 PM
Bioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growth
msn.com - January 28 at 11:09 PM
Q BioMed Inc QBIOQ BioMed Inc QBIO
morningstar.com - November 16 at 1:23 PM
Biomedical Sciences PhD ProgramBiomedical Sciences PhD Program
uwyo.edu - November 13 at 2:32 PM
Q&A: How generative AI could help accelerate biomedical researchQ&A: How generative AI could help accelerate biomedical research
phys.org - November 6 at 8:46 AM
QBIO Q BioMed Inc.QBIO Q BioMed Inc.
seekingalpha.com - August 18 at 4:51 AM
Q BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in EuropeQ BioMed’s chemotherapeutic Uttroside B gets US patent and notice of allowance in Europe
pharmabiz.com - April 17 at 9:36 AM
Q BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder value
proactiveinvestors.com - April 14 at 10:53 AM
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for EuropeQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
finance.yahoo.com - April 14 at 10:53 AM
Q BioMed Stock (OTC:QBIO), Quotes and News SummaryQ BioMed Stock (OTC:QBIO), Quotes and News Summary
benzinga.com - March 3 at 4:23 PM
Q BioMed gets notice of allowable US patent for liver cancer treatment Uttroside BQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside B
proactiveinvestors.com - February 10 at 3:27 PM
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent OfficeQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
finance.yahoo.com - February 10 at 8:27 AM
Short Volatility Alert: Q Biomed IncShort Volatility Alert: Q Biomed Inc
benzinga.com - January 12 at 2:36 PM
Q BioMed Inc. (QBIO)Q BioMed Inc. (QBIO)
finance.yahoo.com - January 1 at 5:15 PM
Q BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin ResearchQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin Research
proactiveinvestors.com - November 14 at 2:22 PM
Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.
finance.yahoo.com - November 14 at 9:20 AM
Q BIOMED PROVIDES SHAREHOLDER UPDATEQ BIOMED PROVIDES SHAREHOLDER UPDATE
prnewswire.com - October 11 at 8:38 AM
Q Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatment
proactiveinvestors.com - September 27 at 1:02 PM
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
finance.yahoo.com - September 27 at 1:02 PM
Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.
finance.yahoo.com - August 25 at 10:16 AM
What to Expect at BIOMEDevice BostonWhat to Expect at BIOMEDevice Boston
mddionline.com - August 10 at 3:59 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Agile Therapeutics logo

Agile Therapeutics

NASDAQ:AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. The company was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Amarantus BioScience logo

Amarantus BioScience

OTCMKTS:AMBS
Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.
GlobeStar Therapeutics logo

GlobeStar Therapeutics

OTCMKTS:GSTC
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.
Q BioMed logo

Q BioMed

OTCMKTS:QBIO
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.